Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 18, 2025

Daiichi Sankyo and AstraZeneca’s Enhertu gains breakthrough therapy status

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to Enhertu, a targeted HER2-directed antibody-drug conjugate (ADC), discovered by Daiichi Sankyo and collaboratively developed and marketed along with AstraZeneca.

Continue
The FDA's decision was based on the results from the DESTINY-Breast09 Phase III trial. Credit: Testalize.me on Unsplash.
July 16, 2025

FDA grants orphan status for AlzeCure’s pain drug candidate

AlzeCure Pharma CEO Martin Jönsson and CMO Märta Segerdal. Credit: AlzeCure Pharma AB.
July 15, 2025

Sun Pharmaceutical launches Leqselvi in US for severe alopecia areata

Leqselvi is an oral drug that selectively inhibits Janus kinases JAK1 and JAK2. Credit: Sun Pharma/PR Newswire.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. FDA grants fast track designation to Sanofi’s SAR446597
  2. Golden Age Health secures rights to promote LX-101 gene therapy in China
  3. Secarna, Vect-Horus partner to develop RNA-targeted therapeutics
  4. Simcere Pharmaceutical seeks China approval for atopic dermatitis treatment
  5. Rallybio sells REV102 programme to Recursion for up to $25m

PRESS RELEASES

Pharmaceutical Business Review
LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
LTS Wins Funding from BARDA’s Patch Forward Prize Competition for Two artnerships
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Two Stories, One Future: Gerresheimer and Bormioli Pharma at Pharmapack 2025
Two Stories, One Future: Gerresheimer and Bormioli Pharma at Pharmapack 2025
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group

Suppliers

Whitepapers

Pharmaceutical Business Review
EVERIC® Pure – The Safe Option Right from the Start
Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme